标题：益气化聚方对代谢综合征患者临床指标和心脑血管疾病高危因子的影响

      作者：张曾 1，杨宏杰 1，傅晓东 2，王文健 3，何燕铭 1    1.上海中医药大学附属岳阳中西医结合医院内分泌科，上海 200437；2.复旦大学附属华山医院中西医结合科，上海 200040；3.上海中医药研究院中西医结合临床研究所，上海 200437

      卷次： 2021年32卷20期

      【摘要】 目的 观察益气化聚方对代谢综合征患者临床指标和心脑血管疾病高危因子的影响。方法 选取90例2019年6~12月在上海中医药大学附属岳阳中西医结合医院就诊的代谢综合征患者，按随机双盲安慰剂对照法分为研究组(益气化聚方+基础治疗)与对照组(安慰剂+基础治疗)各45例，疗程12周。比较两组患者治疗前后的空腹血糖(FPG)、餐后2 h血糖(2 hPPG)、糖化血红蛋白(HbA1c)、空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)、血脂四项、腰围、臀围、腰臀比、收缩压(SBP)、舒张压(DBP)、平均动脉压(MAP)和心脑血管疾病高危因子[纤溶酶原激活物抑制剂(PAI-1)、组织型纤溶酶原激活物(t-PA)、C反应蛋白(CRP)、肿瘤坏死因子(TNF-α)及白介素-6 (IL-6)]水平。结果 治疗12周后，对照组患者治疗前后的各项观察指标比较差异均无统计学意义(P>0.05)，而研究组患者的FPG、2 hPPG、HbA1c、HOMA-IR、腰围、臀围、腰臀比、SBP、DBP、MAP水平与治疗前比较均显著下降，且明显低于对照组治疗后水平，差异均有统计学意义(P<0.05)；治疗12周后，两组患者的CRP、TNF-α、IL-6及PAI-1水平与本组治疗前比较均明显降低，且治疗后研究组患者的CRP、TNF-α、IL-6、PAI-1明显低于对照组，差异均有统计学意义(P<0.05)；两组患者治疗后的 t-PA水平均较治疗前升高，且研究组水平明显高于对照组，差异均有统计学意义(P<0.05)。结论 益气化聚方可明显减轻代谢综合征患者的腹型肥胖，控制血糖、血压，改善胰岛素抵抗，调节心脑血管疾病高危因子，减轻炎症反应、改善纤溶活性。
      【关键词】 益气化聚方；代谢综合征；胰岛素抵抗；炎症因子；纤溶活性
      【中图分类号】 R442.8 【文献标识码】 A 【文章编号】 1003—6350（2021）20—2618—05

Effect of YiqiHuaju formula on clinical indexes and high risk factors of cardiovascular and cerebrovasculardiseases in patients with metabolic syndrome.
ZHANG Zeng 1, YANG Hong-Jie 1, FU Xiao-Dong 2, WANG Wen-Jian 3,HE Yan-Ming 1. 1.Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TCM,Shanghai 200437, CHINA; 2. Department of Integrated Traditional Chinese and Western Medicine, Huashan HospitalAffiliated to Fudan University, Shanghai 200040, CHINA; 3. Clinical Research Institute of Integrated Traditional Chineseand Western Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai 200437, CHINA
【Abstract】 Objective To observe the effect of YiqiHuaju formula on clinical indexes and high risk factors ofcardiovascular and cerebrovascular diseases in patients with metabolic syndrome. Methods A total of 90 patients withmetabolic syndrome treated in Yueyang Integrated Traditional Chinese and Western Medicine Hospital Affiliated toShanghai University of Traditional Chinese Medicine from June to December 2019 were selected and randomly dividedinto study group (YiqiHuaju formula + basic treatment) and placebo control group (placebo + basic treatment) accordingto the double-blind placebo-controlled method, with 45 patients in each group for 12 weeks. The changes of fastingblood glucose (FPG), 2-hour postprandial blood glucose (2 hPPG), glycosylated hemoglobin (HbA1c), fasting insulin